RxDoctor Payments DataLook up a doctor →

Irina Shpak, MD

Critical Care Medicine · Bethpage, NYNPI 1659316826

Payments from drug & device makers

$21,534in general payments, 2019–2025

Across 643 payments — averaging $33.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • GSK$2K
  • AstraZeneca$2K
  • Johnson & Johnson$2K
  • Boehringer Ingelheim$2K
  • Sanofi$1K
  • plus $9K from 45 others

What the payments were for

  • Consulting fees$220%
  • Travel & lodging$2,99914%
  • Food & beverage$18,34685%
  • Education$1591%
  • Gifts$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,534 in reported general payments places this provider in the 90th percentile of 442 critical care medicine providers in New York.

See all critical care medicine providers in New York

Medicare billing

Part B allowed, 2024
$386,174
Medicare patients
789
Services billed
3,131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter162$192,483
Breo ElliptaFluticasone/Vilanterol41$39,020
EliquisApixaban19$21,026
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$21,015
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$9,556
Albuterol Sulfate HfaAlbuterol Sulfate71$2,493
Ventolin HfaAlbuterol Sulfate15$837
Azithromycin29$463
Prednisone56$293
Fluticasone Propionate24$276
Methylprednisolone32$268
Montelukast Sodium25$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$2,442$231,503203 claims
PfizerEliquis$108$21,02619 claims
AstraZenecaBreztri Aerosphere$2,397$21,01523 claims
Boehringer IngelheimStiolto Respimat$1,574$9,55616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 442 critical care medicine providers in New York.

Other critical care medicine in Bethpage

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →